Verastem, Inc. (VSTM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-01-08

Key Insights

Verastem, Inc. has posted an updated corporate presentation on its website, providing investors with the latest information about the company.
The filing does not indicate any major changes or events, suggesting the update is a routine disclosure rather than a significant development.
Investors should review the updated presentation to stay informed about Verastem's business and any potential future developments.

Want the newest filings?

This analysis covers the filing from 2026-01-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2025-12-31

Verastem, Inc. has discontinued the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer to focus resources on the development of VS-7375, an oral KRAS G12D inhibitor, in advanced NSCLC and other solid tumors.
The discontinued RAMP 203 trial had mixed results, with the doublet combination showing a 40% overall response rate in treatment-naive patients but only 9.5% in previously treated patients, and the triplet combination showing a 50% response rate in treatment-naive patients and 36% tumor reduction in previously treated patients.
The decision to discontinue RAMP 203 reflects the evolving treatment landscape for KRAS G12C inhibitors and Verastem's strategic prioritization of programs with the greatest potential impact for patients with advanced lung cancer.

Other reports for Verastem, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.